News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck Serono's Erbitux Significantly Extends Survival by 7.5 Months in mCRC RAS Wild-Type Patients When Compared With Bevacizumab: New Analysis of FIRE-3 AIO Study


9/30/2013 10:44:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Darmstadt, Germany/Amsterdam, The Netherlands, September 28, 2013 – Merck Serono, the biopharmaceutical division of Merck, today announced that the German cooperative investigator group AIO (Arbeitsgemeinschaft Internistische Onkologie) reported new data from the Phase III head-to-head clinical trial FIRE-3, which show a clinically relevant improvement from Erbitux® (cetuximab) plus FOLFIRI versus bevacizumab plus FOLFIRI as 1st line treatment in metastatic colorectal cancer (mCRC) in patients with RAS wild-type tumors.1 The new data, from a preplanned exploratory analysis, were presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO). The analysis shows a 7.5-month increase in median overall survival (OS) in mCRC patients with RAS wild-type tumors ((n=342); defined as having no mutations in exons 2, 3 and 4 of KRAS and NRAS), receiving 1st line Erbitux plus FOLFIRI compared with patients receiving bevacizumab plus FOLFIRI (OS: 33.1 months vs. 25.6 months, respectively; hazard ratio [HR]: 0.70; p=0.011). In a post hoc analysis of the patient group with any RAS mutations (n=178), patients who received Erbitux plus FOLFIRI 1st line reached an OS of 20.3 months vs. 20.6 months in the group that was treated with bevacizumab plus FOLFIRI (HR: 1.09; p=0.60).1

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES